(+/-)-ethyl 4-phenyl-3,4-dihydro-2H-benzo[b][1,4]oxazine-2-carboxylate | 281658-45-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (+/-)-ethyl 4-phenyl-3,4-dihydro-2H-benzo[b][1,4]oxazine-2-carboxylate
• 英文别名: Ethyl 3,4-dihydro-4-phenyl-2H-1,4-benzoxazine-2-carboxylate；ethyl 4-phenyl-2,3-dihydro-1,4-benzoxazine-2-carboxylate
• CAS: 281658-45-5
• 化学式: C₁₇H₁₇NO₃
• 分子量: 283.327
• InChiKey: LFQRQIXOQWPUJE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (+/-)-ethyl 4-phenyl-3,4-dihydro-2H-benzo[b][1,4]oxazine-2-carboxylate 在 吡啶 、 锂硼氢 、 三乙胺 作用下， 以 二甲基亚砜 为溶剂， 生成 [3-(5-Fluoro-1H-indol-3-yl)-propyl]-(4-phenyl-3,4-dihydro-2H-benzo[1,4]oxazine-2-yl-methyl)-amine
  参考文献：
  名称：

  Studies toward the discovery of the next generation of antidepressants. Part 5: 3,4-Dihydro-2H-benzo[1,4]oxazine derivatives with dual 5-HT1A receptor and serotonin transporter affinity

  摘要：

  The design, synthesis, and structure-activity relationship of two novel classes of benzoxazine derivatives with dual selective serotonin reuptake inhibitors and 5-HT1A receptor activities are described. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.11.054
• 作为产物：
  描述：

  2,3-二溴丙酸乙酯 在 potassium carbonate 、 对甲苯磺酸 作用下， 以 丙酮 、 甲苯 为溶剂， 生成 (+/-)-ethyl 4-phenyl-3,4-dihydro-2H-benzo[b][1,4]oxazine-2-carboxylate
  参考文献：
  名称：

  Studies toward the discovery of the next generation of antidepressants. Part 5: 3,4-Dihydro-2H-benzo[1,4]oxazine derivatives with dual 5-HT1A receptor and serotonin transporter affinity

  摘要：

  The design, synthesis, and structure-activity relationship of two novel classes of benzoxazine derivatives with dual selective serotonin reuptake inhibitors and 5-HT1A receptor activities are described. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.11.054

文献信息

• Beta-secretase modulators and methods of use
  申请人：Albrecht K. Brian

  公开号：US20070185103A1

  公开（公告）日：2007-08-09

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, B, R 3 , R 4 , R 5 , i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.

  本发明涉及一类新的化合物，用于调节Beta-分泌酶酶活性和治疗Beta-分泌酶介导的疾病，包括阿尔茨海默病（AD）和相关疾病。 在一种实施方式中，该化合物具有一般式I，其中A，B，R3，R4，R5，i和j在此定义。 本发明还包括包括一种或多种I式化合物的制药组合物，以及使用这些化合物的方法，包括通过向受体注射I式化合物或包含它们的组合物来治疗AD和相关疾病。 本发明还包括II式和III式的进一步实施方式，以及用于制备本发明化合物的中间体和过程。
• Beta-Secretase modulators and methods of use
  申请人：Amgen Inc.

  公开号：US07872009B2

  公开（公告）日：2011-01-18

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, B, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.

  本发明涉及一种新型化合物类别，可用于调节β-秘鲁酶酶活性和治疗β-秘鲁酶介导的疾病，包括阿尔茨海默病（AD）和相关病症。在一种实施例中，该化合物具有一般式I，其中A、B、R3、R4、R5、i和j在此定义。本发明还包括包括一种或多种I式化合物的制药组合物，使用这些化合物的方法，包括通过将I式化合物或包括它们的组合物用于治疗AD和相关疾病来给予受试者。本发明还包括II式和III式的进一步实施例，中间体和制备本发明化合物的有用过程。
• BETA-SECRETASE MODULATORS AND METHODS OF USE
  申请人：Albrecht Brian K.

  公开号：US20110118250A1

  公开（公告）日：2011-05-19

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, B, R 3 , R 4 , R 5 , i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.

  本发明涉及一类新型化合物，可用于调节β-分泌酶酶活性和治疗β-分泌酶介导的疾病，包括阿尔茨海默病（AD）和相关疾病。在一种实施例中，所述化合物具有一般式I，其中A、B、R3、R4、R5、i和j在此被定义。本发明还包括包括一种或多种式I化合物的制药组合物，以及使用这些化合物的方法，包括将式I化合物或包含它们的组合物用于治疗AD和相关疾病，通过将式I化合物或包含它们的组合物用于给予受试者的方法。本发明还包括式II和III的进一步实施例，以及用于制备本发明化合物的中间体和方法。
• WO2007/62007
  申请人：——

  公开号：——

  公开（公告）日：——
• Studies toward the discovery of the next generation of antidepressants. Part 5: 3,4-Dihydro-2H-benzo[1,4]oxazine derivatives with dual 5-HT1A receptor and serotonin transporter affinity
  作者：Dahui Zhou、Boyd L. Harrison、Uresh Shah、Terrance H. Andree、Geoffrey A. Hornby、Rosemary Scerni、Lee E. Schechter、Deborah L. Smith、Kelly M. Sullivan、Richard E. Mewshaw

  DOI：10.1016/j.bmcl.2005.11.054

  日期：2006.3

  The design, synthesis, and structure-activity relationship of two novel classes of benzoxazine derivatives with dual selective serotonin reuptake inhibitors and 5-HT1A receptor activities are described. (C) 2005 Elsevier Ltd. All rights reserved.